Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (En...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3849430?pdf=render |
id |
doaj-688f74a69bab4601af81fd692d862712 |
---|---|
record_format |
Article |
spelling |
doaj-688f74a69bab4601af81fd692d8627122020-11-25T01:28:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8238010.1371/journal.pone.0082380Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.Jeff AlexanderJason MendyLo VangJenny B AvanziniFermin GardunoDarly J ManayaniGlenn IshiokaPeggy FarnessLi-Hua PingRonald SwanstromRobert ParksHua-Xin LiaoBarton F HaynesDavid C MontefioriCelia LaBrancheJonathan SmithMarc GurwithTim MayallThere is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120) were evaluated.The recombinant Ad4 vectors were generated with a full deletion of the E3 region of Ad4 to accommodate the env gene sequences. The vaccine candidates were assessed in vitro following infection of A549 cells for Env-specific protein expression and for posttranslational transport to the cell surface as monitored by the binding of broadly neutralizing antibodies (bNAbs). The capacity of the Ad4Env vaccines to induce humoral immunity was evaluated in rabbits for Env gp140 and V1V2-specific binding antibodies, and HIV-1 pseudovirus neutralization. Mice immunized with the Ad4Env160 vaccine were assessed for IFNγ T cell responses specific for overlapping Env peptide sets.Robust Env protein expression was confirmed by western blot analysis and recognition of cell surface Env gp160 by multiple bNAbs. Ad4Env vaccines induced humoral immune responses in rabbits that recognized Env 1086 gp140 and V1V2 polypeptide sequences derived from 1086 clade C, A244 clade AE, and gp70 V1V2 CASE A2 clade B fusion protein. The immune sera efficiently neutralized tier 1 clade C pseudovirus MW965.26 and neutralized the homologous and heterologous tier 2 pseudoviruses to a lesser extent. Env-specific T cell responses were also induced in mice following Ad4Env160 vector immunization.The Ad4Env vaccine vectors express high levels of Env glycoprotein and induce both Env-specific humoral and cellular immunity thus supporting further development of this new Ad4 HIV-1 Env vaccine platform in Phase 1 clinical trials.http://europepmc.org/articles/PMC3849430?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeff Alexander Jason Mendy Lo Vang Jenny B Avanzini Fermin Garduno Darly J Manayani Glenn Ishioka Peggy Farness Li-Hua Ping Ronald Swanstrom Robert Parks Hua-Xin Liao Barton F Haynes David C Montefiori Celia LaBranche Jonathan Smith Marc Gurwith Tim Mayall |
spellingShingle |
Jeff Alexander Jason Mendy Lo Vang Jenny B Avanzini Fermin Garduno Darly J Manayani Glenn Ishioka Peggy Farness Li-Hua Ping Ronald Swanstrom Robert Parks Hua-Xin Liao Barton F Haynes David C Montefiori Celia LaBranche Jonathan Smith Marc Gurwith Tim Mayall Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. PLoS ONE |
author_facet |
Jeff Alexander Jason Mendy Lo Vang Jenny B Avanzini Fermin Garduno Darly J Manayani Glenn Ishioka Peggy Farness Li-Hua Ping Ronald Swanstrom Robert Parks Hua-Xin Liao Barton F Haynes David C Montefiori Celia LaBranche Jonathan Smith Marc Gurwith Tim Mayall |
author_sort |
Jeff Alexander |
title |
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. |
title_short |
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. |
title_full |
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. |
title_fullStr |
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. |
title_full_unstemmed |
Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C. |
title_sort |
pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing hiv-1 envelope 1086 clade c. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
There is a well-acknowledged need for an effective AIDS vaccine that protects against HIV-1 infection or limits in vivo viral replication. The objective of these studies is to develop a replication-competent, vaccine vector based on the adenovirus serotype 4 (Ad4) virus expressing HIV-1 envelope (Env) 1086 clade C glycoprotein. Ad4 recombinant vectors expressing Env gp160 (Ad4Env160), Env gp140 (Ad4Env140), and Env gp120 (Ad4Env120) were evaluated.The recombinant Ad4 vectors were generated with a full deletion of the E3 region of Ad4 to accommodate the env gene sequences. The vaccine candidates were assessed in vitro following infection of A549 cells for Env-specific protein expression and for posttranslational transport to the cell surface as monitored by the binding of broadly neutralizing antibodies (bNAbs). The capacity of the Ad4Env vaccines to induce humoral immunity was evaluated in rabbits for Env gp140 and V1V2-specific binding antibodies, and HIV-1 pseudovirus neutralization. Mice immunized with the Ad4Env160 vaccine were assessed for IFNγ T cell responses specific for overlapping Env peptide sets.Robust Env protein expression was confirmed by western blot analysis and recognition of cell surface Env gp160 by multiple bNAbs. Ad4Env vaccines induced humoral immune responses in rabbits that recognized Env 1086 gp140 and V1V2 polypeptide sequences derived from 1086 clade C, A244 clade AE, and gp70 V1V2 CASE A2 clade B fusion protein. The immune sera efficiently neutralized tier 1 clade C pseudovirus MW965.26 and neutralized the homologous and heterologous tier 2 pseudoviruses to a lesser extent. Env-specific T cell responses were also induced in mice following Ad4Env160 vector immunization.The Ad4Env vaccine vectors express high levels of Env glycoprotein and induce both Env-specific humoral and cellular immunity thus supporting further development of this new Ad4 HIV-1 Env vaccine platform in Phase 1 clinical trials. |
url |
http://europepmc.org/articles/PMC3849430?pdf=render |
work_keys_str_mv |
AT jeffalexander preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT jasonmendy preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT lovang preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT jennybavanzini preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT fermingarduno preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT darlyjmanayani preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT glennishioka preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT peggyfarness preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT lihuaping preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT ronaldswanstrom preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT robertparks preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT huaxinliao preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT bartonfhaynes preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT davidcmontefiori preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT celialabranche preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT jonathansmith preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT marcgurwith preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec AT timmayall preclinicaldevelopmentofarecombinantreplicationcompetentadenovirusserotype4vectorvaccineexpressinghiv1envelope1086cladec |
_version_ |
1725100301530169344 |